Introduction
============

Neuroendocrine tumors (NET) are the most common neoplasms of the appendix. These tumors are classified as typical NET (TNET), goblet cell carcinoid (GCC), and atypical GCC histologies. Atypical GCC is defined in the literature as mixed adenoneuroendocrine carcinomas. Ex-goblet or composite-goblet are further classified into signet ring cell carcinoid (SRCC) and poorly differentiated adenocarcinoid of the appendix \[[@b1-crt-2015-029]\]. Nomenclature and classification of disease are undecided. Appendiceal GCCs are rare tumors constituting 2.5%-5% of all primary appendiceal neoplasms. These tumors have a distinctive morphology showing tight clusters of cells with compact nuclei and abundant intracytoplasmic mucin resembling goblet or signet ring cells often with admixed enterochromaffin cells \[[@b2-crt-2015-029]\]. Pathologic features of GCC include presence of large mucin filled cells with crescent nuclei arranged in small clumps or rosettes mixed with cells of typical carcinoid appearance that stain positive for chromogranin A \[[@b3-crt-2015-029]\]. The outcome of appendiceal NET is influenced by the histologic features of the disease. Patients with TNET have a 5-year survival ranging from 60% to 84% \[[@b4-crt-2015-029],[@b5-crt-2015-029]\], with the most common site of metastasis being the liver. On the other hand, atypical GCC have a more aggressive clinical course with an increased incidence of lymph node and distant metastases, along with a lower 5-year survival ranging from 36% to 56% \[[@b5-crt-2015-029]-[@b7-crt-2015-029]\]. Current management of GCC and atypical GCC is based on very limited data from small single institutional experiences.

The rarity of appendiceal NET, GCC, and SRCC limits the ability to conduct appropriate randomized clinical trials to explore the optimal management. To assess the role of clinicopathologic features in survival of NET, GCC, and SRCC patients, the outcome of cases reported to the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program was evaluated. Furthermore, to characterize the management of NET, GCC, and SRCC, a treatment strategy based on results of current analysis, published literature and institutional experience is suggested.

Materials and Methods
=====================

1. Patients
-----------

SEER data collected between 1973 and 2011 was used to identify cases with appendiceal TNET, GCC, and SRCC. The SEER registry data collection began in the early 1970s and gradually expanded from the original nine to the current 18 registries that now account for over a quarter of the United States population \[[@b6-crt-2015-029]\].

Eligibility criteria included International Classification of Diseases for Oncology third edition (ICD-O-3) codes for primary site of appendix and histologic types of TNET (8240, 8241, 8242, 8246, and 8270), GCC (8243, 8244, 8245, and 8249), and SRCC (8490). Information regarding age at diagnosis, sex, race, year of diagnosis, grade, histology, tumor location, type of surgery, vital status and duration of follow-up, was extracted from the SEER database.

2. Statistical analysis
-----------------------

The patients' characteristics were compared among three histologic types: TNET, GCC, and SRCC by chi-square test for race, sex, and stage, and Kruskal-Wallis test for age. Survival functions were estimated by the Kaplan-Meier method and log-rank test was used to assess the difference in overall survival (OS) between three histologic types: TNET, GCC, and SRCC \[[@b8-crt-2015-029]\]. Univariate survival analysis for each covariate was carried out using the Cox proportional hazards model \[[@b9-crt-2015-029]\]. The proportional hazard assumption was checked. The multivariate survival analysis of histology was conducted after adjusting for age, race, and sex using a backward variable selection method with an alpha level of removal of 0.1. The model was stratified by stage since there was an interaction effect between histology and stage on OS. The SAS ver. 9.3 (SAS Institute Inc., Cary, NC) was used for data analyses. Null hypotheses of no difference were rejected if p-values were less than 0.05, or, equivalently, if the 95% confidence intervals (CIs) of risk point estimates excluded 1.

Results
=======

1. Characteristics of patients with TNET, GCC, and SRCC
-------------------------------------------------------

The SEER database yielded 1,021 TNET patients, 1,582 with GCC, and 534 SRCC patients. Between 1973 and 2011, the incidence of TNET, GCC, and SRCC increased. In 2011, the incidence of TNET reached 6.7, GCC was 0.3, and SRCC was two patients per 100,000 persons. Baseline characteristics are compared between appendiceal TNET, GCC, and SRCC in [Table 1](#t1-crt-2015-029){ref-type="table"}. Significant differences in age at presentation (p \< 0.001), sex distribution (p \< 0.001), surgery (p \< 0.001), type of surgery (appendectomy, right hemicolectomy, and surgery not otherwise specified) (p \< 0.001), and stage (p \< 0.001) were observed between the TNET, GCC, and SRCC. TNET patients presented younger (median age of 41 vs. 54.5 in GCC and 57 years in SRCC). Female patients constituted a higher proportion among TNET cases (66.2% vs. 61.4% of SRCC and 48.5% of GCC). Advanced stage disease was more common in SRCC patients (60.9% vs. 14.1% in TNET and 10.4% in GCC). A higher proportion of white patients was observed in all three histologies, but the difference was not statistically significant (p=0.11).

Surgery was performed in 839 (82.6%) of the TNET patients, 1,365 (86.4%) of the GCC, and 419 (78.6%) of the SRCC patients, and these differences were statistically significant (p \< 0.001). Appendectomy was performed in 52 of patients with TNET (5.9%) as compared to 54 of the GCC (3.9%), and 9 of the SRCC (2.1%). Right hemicolectomy was performed in 484 of the TNET (54.9%), 1,208 of the GCC (86.4%), and 301 of the SRCC patients (70.7%). The differences in type of surgery were significantly different among the three histologies (p \< 0.001). [Table 2](#t2-crt-2015-029){ref-type="table"} summarizes the type of surgery based on histology and stage.

2. Survival outcome of patients with TNET, GCC, and SRCC
--------------------------------------------------------

The median overall survival (mOS) for appendiceal SRCC was 24 months. The mOS for GCC and TNET were not reached at the time of this analysis. Comparing survival among the different histologies, TNET had a survival advantage over GCC (hazard ratio \[HR\], 0.56; 95% CI, 0.45 to 0.69; p=0.005), which had a better survival over SRCC histology (HR, 0.22; 95% CI, 0.19 to 0.26; p \< 0.001) ([Table 3](#t3-crt-2015-029){ref-type="table"}). In each stage, TNET and GCC had significant survival advantages over SRCC ([Figs. 1](#f1-crt-2015-029){ref-type="fig"}[](#f2-crt-2015-029){ref-type="fig"}-[3](#f3-crt-2015-029){ref-type="fig"}). In the localized stage, mOS was not reached for any of the three histologies. Comparing SRCC, the HR for survival was 0.26 (0.15-0.46; p \< 0.001) for TNET and 0.42 (0.26-0.69; p \< 0.001) for GCC. For regional stage disease, the mOS for SRCC was 35 months (95% CI, 30 to 45), while mOS for GCC and TNET were not reached. The TNET regional disease stage patients had survival advantage over GCC (HR, 0.37; 95% CI, 0.24 to 0.59; p \< 0.001). GCC had better survival compared to SRCC patients with regional disease stage (HR, 0.29; 95% CI, 0.21 to 0.40; p \< 0.001). For distant disease stage, mOS was 32 (95% CI, 13 to not reached) for TNET, 23 (95% CI, 18 to 28) for GCC, and 15 months (95% CI, 13 to 18) for SRCC. In this group, TNET patients had survival advantage over GCC (HR, 0.61; 95% CI, 0.44 to 0.83; p=0.002). GCC patients survived better compared to SRCC patients with distant disease (HR, 0.73; 95% CI, 0.60 to 0.90; p=0.003).

After adjusting for age, stage, and histology, there was a statistically significant difference in survival for SRCC patients treated with hemicolectomy compared to appendectomy (p=0.01). There was no significant difference in survival for TNET and GCC patients based the type of surgery (p=0.21 and p=0.94, respectively). In the multivariate analysis stratified by stage and age, there was a statistically significant difference in survival favoring TNET (HR, 0.41; 95% CI, 0.31 to 0.55) and GCC (HR, 0.59; 95% CI, 0.48 to 0.72) over SRCC.

Discussion
==========

Appendiceal TNET, GCC and SRCC are distinct clinicopathologic entities. The analysis of the SEER registry sample confirms the differences in presentation and outcome of these diseases. TNET tend to occur at a younger age and has a less aggressive clinical course, early stage at presentation and significantly improved OS. At the other end of the disease spectrum, SRCC tend to occur in older patients. The aggressive nature of SRCC is reflected by the high risk of distant metastasis at diagnosis, and worse survival outcomes even when controlled for stage.

The reported sex distribution in TNET ranges from a female preponderance (63% to 73%) to evenly distributed \[[@b4-crt-2015-029],[@b10-crt-2015-029]\]. Similarly for GCC, literature reports range from female gender predominance \[[@b1-crt-2015-029],[@b11-crt-2015-029],[@b12-crt-2015-029]\], to equal distribution \[[@b4-crt-2015-029],[@b10-crt-2015-029],[@b11-crt-2015-029]\]. Most of these series are based on small numbers of patients from single institution studies. The current report confirms, using a large national database, that there are gender differences in distribution of TNET, GCC, and SRCC (p \< 0.001). For SRCC histology, we confirmed a higher prevalence amongst women in this SEER analysis as compared to GCC histology, consistent with a previous report \[[@b1-crt-2015-029]\]. Additionally, appendiceal SRCC appear to be clinically similar to right-sided, microsatellite unstable, signet ring cell colon adenocarcinoma with respect to gender distribution, age of diagnosis and outcome. This raises the question whether appendiceal SRCC and right colon adenocarcinomas behave more like a single disease entity distinct from other colorectal cancer (CRC) adenocarcinoma and appendiceal GCC. This apparent difference in clinical behavior will require further characterization through genomic analysis of CRC SRCC, appendiceal SRCC and typical GCC. Hence, a molecularly based classification may facilitate prognostication and perhaps target identification for future clinical trials.

The analysis of the SEER data confirms that histology and stage at presentation are the major determinants of outcome. The high risk of metastatic disease in the SRCC patients confirms the aggressive clinical behavior of this tumor. The rate of metastasis at diagnosis in SRCC histology ranges from 14% \[[@b4-crt-2015-029]\] to 63% \[[@b1-crt-2015-029]\]. The survival advantage for TNET and GCC over SRCC persisted after controlling for the difference in stage distribution. Similar observations were reported with 5-year survival of patients with advanced stage GCC, SRCC and poorly differentiated adenocarcinoid tumor being 100%, 38%, and 0%, respectively \[[@b1-crt-2015-029]\].

Given their rarity, there is no consensus on the management of appendiceal TNET, GCC, or SRCC. The treatments employed included surgical resection and cytoreduction of primary tumor and metastatic sites, intraperitoneal chemotherapy and systemic fluorouracil-based chemotherapy. Debulking surgery and hyperthermic intraperitoneal chemotherapy treatment is not well-established in appendiceal NET, GCC, and SRCC tumors, although it improves appendiceal mucinous adecarcinoma \[[@b13-crt-2015-029],[@b14-crt-2015-029]\]. All of these treatment options lack evidence of efficacy. Clinically, the management decisions are usually based on histologic subtype and stage, as well as the patient's performance status. Early stage TNET, GCC, or SRCC should be managed surgically, although the extent of surgery is an open question. Historically, the accepted surgical dogma was that simple appendectomy is sufficient for resection of TNET less than 2 cm \[[@b15-crt-2015-029]\]. Recent reports demonstrated that appendiceal TNET measuring less than 2 cm may have regional nodal involvement, raising the question whether a more extensive surgery than simple appendectomy is required irrespective of size \[[@b16-crt-2015-029]\]. These observations are further supported by a SEER analysis where 32.8% of patients with NET less than 2 cm in size (20/61) had lymph node metastasis \[[@b4-crt-2015-029]\]. The North American Neuroendocrine Tumor Society (NANETS) \[[@b17-crt-2015-029]\] and European Neuroendocrine Tumor Society (ENETS) \[[@b18-crt-2015-029]\] guidelines suggest right hemicolectomy for all tumors \> 2 cm or presence of deep mesoappendiceal invasion, positive or unclear margins, higher proliferative rate (grade 2), angi olymphatic invasion, and mixed histology, irrespective of tumor size. There is no accepted consensus regarding surgical resection for GCC or SRCC tumors. While simple appendectomy may be adequate for early stage GCC \[[@b19-crt-2015-029],[@b20-crt-2015-029]\], cecal involvement or high mitotic count index should be an indication for right hemicolectomy \[[@b19-crt-2015-029],[@b21-crt-2015-029],[@b22-crt-2015-029]\]. Surgery for SRCC should always involve a right hemicolectomy due to the high likelihood of lymph node metastasis, irrespective of the size of the primary appendiceal mass. This is supported by our analysis of the SEER data that indicates superior survival for patients with SRCC who undergo right hemicolectomy. The role of surgical resection of the ovaries in female patients with localized SRCC or GCC remains controversial \[[@b1-crt-2015-029],[@b12-crt-2015-029],[@b22-crt-2015-029]\]. A summary of the NANETS \[[@b17-crt-2015-029]\] and ENETS \[[@b18-crt-2015-029]\] guidelines is provided in [Table 4](#t4-crt-2015-029){ref-type="table"}.

Unlike CRC adenocarcinoma, the role of adjuvant therapy is not established for TNET, GCC, or SRCC. Based on our analysis, patients with TNET have an excellent OS and therefore adjuvant therapy is not indicated. On the other hand, given the high risk of systemic metastasis in SRCC, we recommend offering adjuvant therapy for all patients undergoing resection. In our analysis of the SEER sample, the outcome of patients with early stage GCC appears favorable, suggesting that patients with GCC should be considered for adjuvant therapy only if they have high risk features such as cecal invasion, perforation, or lymph node involvement. Management of advanced stage disease in TNET should be similar to midgut NET. For GCC patients with advanced stage disease, options of treatments include peritoneal debulking with intraperitoneal chemotherapy for patient with limited peritoneal disease or systemic fluorouracilbased chemotherapy. For SRCC patients, our recommendations include treating with systemic fluorouracil-based chemotherapy initially and only consider peritoneal resection for patients with good response to initial therapy. A summary of the proposed treatment algorithm is provided in [Fig. 4](#f4-crt-2015-029){ref-type="fig"}.

Predictive and prognostic biomarkers are not well defined for these diseases. In an attempt to identify gene variations between appendiceal mucinous adenocarcinoma and GCC, we profiled nine GCC samples using second-generation gene sequencing. Only one patient with GCC (11%) had *KRAS* mutation, and two had *TP53* mutation; *MYC*, *SMAD4*, and *APC* mutations were absent in GCC \[[@b23-crt-2015-029]\]. Stancu et al. \[[@b24-crt-2015-029]\] and Dimmler et al. \[[@b25-crt-2015-029]\] proved the absence of *KRAS* mutations in 16 and 14 GCC samples. In the light of its rarity, molecular differentiation markers for appendiceal TNET, GCC, and SRCC were never studied. Further confirmation with larger studies is needed to evaluate pathologic genomic sequencing for the three histologies in order to detect differences in survival and possible future biomarkers that predict response to specific target treatments.

Conclusion
==========

This is the largest report to date for patients with appendiceal NET. The SEER registry findings confirm the distinct clinical entities of TNET, GCC, and SRCC with respect to presentation and outcome. Careful evaluation of the morphologic features and appropriate pathologic classification are crucial for treatment. A treatment strategy is presented based on the experience of both institutions.
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![Kaplan-Meier curves of localized appendiceal cancers comparing survival in different histologies. Localized typical neuroendocrine tumor (TNET) (hazard ratio \[HR\], 0.26; 95% confidence interval \[CI\], 0.15 to 0.46; p \< 0.001) and goblet cell carcinoid (GCC) tumors (HR, 0.42; 95% CI, 0.26 to 0.69; p=0.001) have survival advantage, as compared with signet-ring cell cancer (SRCC) histology.](crt-2015-029f1){#f1-crt-2015-029}

![Kaplan-Meier curves of regional disease comparing survival in different histologies. Regional typical neuroendocrine tumor (TNET) has survival advantage over goblet cell carcinoid (GCC) tumors (hazard ratio \[HR\], 0.37; 95% confidence interval \[CI\], 0.24 to 0.59; p \< 0.001), which has a better survival, in turn, as compared to signet-ring cell cancer (SRCC) histology (HR, 0.29; 95% CI, 0.21 to 0.40; p \< 0.001).](crt-2015-029f2){#f2-crt-2015-029}

![Kaplan-Meier curves of distant disease comparing survival in different histologies. Distant typical neuroendocrine tumor (TNET) has survival advantage over goblet cell carcinoid (GCC) tumors (hazard ratio \[HR\], 0.61; 95% confidence interval \[CI\], 0.44 to 0.83; p=0.002), which has a better survival, in turn, as compared to signet-ring cell cancer (SRCC) histology (HR, 0.73; 95% CI, 0.60 to 0.90; p=0.003).](crt-2015-029f3){#f3-crt-2015-029}

![Summary of the proposed treatment algorithm for typical NET (A), goblet cell carcinoid (B), and signet-ring cell cancer (SRCC) (C) tumors. Chemotherapy is fluropyrimidine based. NET, neuroendocrine tumor; HIPEC, hyperthermic intraperitoneal chemotherapy. ^a)^HIPEC treatment treatment is controversial in SRCC.](crt-2015-029f4){#f4-crt-2015-029}

###### 

SEER data patient characteristics for TNET, GCC, and SRCC appendiceal tumors

  Characteristic   TNET (n=1,021)   GCC (n=1,582)   SRCC (n=534)   p-value^[a)](#tfn2-crt-2015-029){ref-type="table-fn"}^
  ---------------- ---------------- --------------- -------------- --------------------------------------------------------
  **Age (yr)**     41 (9-89)        54.5 (10-99)    57 (25-90)     \< 0.001
  **Race**                                                         
   White           812 (79.5)       1,300 (82.2)    425 (79.6)     0.11
   Black           77 (7.5)         133 (8.4)       42 (7.8)       
   Other           114 (11.2)       138 (8.7)       65 (12.2)      
   Missing         18 (1.8)         11 (0.7)        2 (0.4)        
  **Sex**                                                          
   Female          676 (66.2)       768 (48.5)      328 (61.4)     \< 0.001
   Male            345 (33.8)       814 (51.5)      206 (38.6)     
  **Stage**                                                        
   Localized       578 (56.6)       927 (58.6)      90 (16.8)      \< 0.001
   Regional        300 (29.4)       408 (25.8)      116 (21.7)     
   Distant         102 (10)         219 (14.1)      321 (60.1)     
   Missing         41 (4)           28 (1.8)        7 (1.3)        
  **Surgery**                                                      
   Yes             854 (83.6)       1,382 (87.3)    420 (78.6)     \< 0.001
   No              67 (11.6)        82 (5.2)        9 (1.7)        
   Missing         100 (9.8)        118 (7.4)       105 (19.7)     

Values are presented as median (range) or number (%). SEER, Surveillance Epidemiology and End Results; TNET, typical neuroendocrine tumor; GCC, goblet cell carcinoid; SRCC, signet-ring cell cancer.

p-value is calculated by Kruskal-Wallis test for age; chi-square test for race.

###### 

Summary of the type of surgery done for each histology at different stages for appendiceal TNET, GCC, and SRCC

  Type of surgery        TNET         GCC          SRCC
  ---------------------- ------------ ------------ ------------
  **Localized**          510          845          81
   Appendectomy          40 (7.8)     42 (5)       3 (3.7)
   Right hemicolectomy   256 (50.2)   753 (87)     73 (90.1)
   Surgery NOS           214 (43)     50 (5.9)     5 (6.2)
  **Regional**           273          375          108
   Appendectomy          7 (2.6)      10 (2.7)     2 (1.8)
   Right hemicolectomy   193 (70.7)   352 (93.9)   105 (97.2)
   Surgery NOS           73 (26.7)    13 (3.5)     1 (0.9)
  **Distant**                                      
   Debulking surgery     71           162          231

Values are presented as number (%). TNET, typical neuroendocrine tumor; GCC, goblet cell carcinoid; SRCC, signet-ring cell cancer; NOS, not otherwise specified.

###### 

Univariate and multivariate analysis showing differences in histology, race, sex, age, and stage

  Covariate                                                         Univariate analysis   Multivariate analysis                                                     
  ----------------------------------------------------------------- --------------------- ----------------------- ------------------------------------------------- ----------
  **Histology**                                                                                                                                                     
   GCC                                                              0.22 (0.19-0.26)      \< 0.001                0.59 (0.48-0.72)                                  \< 0.001
   TNET                                                             0.12 (0.10-0.15)                              0.41 (0.31-0.55)                                  
   SRCC                                                             1 (reference)                                 1 (reference)                                     
  **Race**                                                                                                                                                          
   African American                                                 1.14 (0.88-1.47)      0.012                   0.59 (0.48-0.72)                                  0.083
   Caucasian                                                        1.37 (1.11-1.70)                              0.41 (0.31-0.55)                                  
   Other                                                            1 (reference)                                 1 (reference)                                     
  **Sex**                                                                                                         ^[b)](#tfn6-crt-2015-029){ref-type="table-fn"}^   
   Female                                                           1.06 (0.92-1.22)      0.391                                                                     \-
   Male                                                             1 (reference)                                                                                   
  **Age**                                                           1.05 (1.04-1.05)      \< 0.001                ^[a)](#tfn5-crt-2015-029){ref-type="table-fn"}^   \-
  **Stage**                                                                                                       ^[a)](#tfn5-crt-2015-029){ref-type="table-fn"}^   
   Localized                                                        0.07 (0.06-0.08)      \< 0.001                                                                  \-
   Regional                                                         0.16 (0.13-0.19)                                                                                
   Distant                                                          1 (reference)                                                                                   
  **Surgery type^[c)](#tfn7-crt-2015-029){ref-type="table-fn"}^**                                                 0.062                                             
   Appendectomy                                                     0.19 (0.12-0.31)      \< 0.001                1.24 (0.71-2.18)                                  \-
   Hemicolectomy                                                    0.24 (0.20-0.30)                              0.81 (0.65-1.02)                                  
   Surgery NOS                                                      1 (reference)                                 1 (reference)                                     

HR, hazard ratio; CI, confidence interval; GCC, goblet cell carcinoid; TNET, typical neuroendocrine tumor; SRCC, signet-ring cell cancer; NOS, not otherwise specified.

Stratified by stage and age at diagnosis,

Gender was dropped through a backward variable selection method (p \> 0.1),

Partial colectomy was classified as hemicolectomy.

###### 

Summary of the differences in the NANETS and ENETS guidelines for treatment of TNET and GCC patients

                NANETS \[[@b17-crt-2015-029]\]                               ENETS \[[@b18-crt-2015-029]\]
  ------------- ------------------------------------------------------------ -------------------------------------------------------------------------------
  **TNET**                                                                   
   Localized    Appendectomy                                                 Appendectomy
                 \< 1 cm, no lymphovascular or mesoappendiceal involvement    Size \< or = 1, absence of subserosal or mesoappendix involvement
                Right hemicolectomy                                          Right hemicolectomy
                 Base of the appendix                                         Involved margins
                 \> 2 cm                                                      \> 2 cm mass
                 Intermediate grade                                           Grade 2 disease
                 Lymph node involvement                                       Base of the appendix involved
                No adjuvant treatment is recommended                         No adjuvant treatment is recommended
   Metastatic   As midgut                                                    As midgut
  **GCC**                                                                    
   Localized    \-                                                           GCC is considered mixed adeno-neuroendocrine carcinoma
                                                                             Right hemicolectomy
                                                                              Always recommended even after appendectomy (within 3 months of appendectomy)
                                                                              Salpingo-oophorectomy recommended in female patients
   Metastatic   \-                                                           Treat as adenocarcinoma with fluoropyrimidine-based chemotherapy

NANETS, North American Neuroendocrine Tumor Society; ENETS, European Neuroendocrine Tumor Society; TNET, typical neuroendocrine tumor; GCC, goblet cell carcinoid.
